title: BRAF-mutations in non-small cell lung cancer.
abstract: OBJECTIVE
  Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation.
  
  
  METHODS
  NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method.
  
  
  RESULTS
  We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 2.3% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%).
  
  
  CONCLUSIONS
  BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC.
authors.affiliation: Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: otr@ous-hf.no.
authors.forename: Odd Terje
authors.initials: OT
authors.lastname: Brustugun
authors.affiliation: Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Asma Malik
authors.initials: AM
authors.lastname: Khattak
authors.affiliation: Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Anette Kjoshagen
authors.initials: AK
authors.lastname: Trømborg
authors.affiliation: Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Marzieh
authors.initials: M
authors.lastname: Beigi
authors.affiliation: Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Klaus
authors.initials: K
authors.lastname: Beiske
authors.affiliation: Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Marius
authors.initials: M
authors.lastname: Lund-Iversen
authors.affiliation: Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
authors.forename: Åslaug
authors.initials: Å
authors.lastname: Helland
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D012307:Risk Factors; D014178:Translocation, Genetic; D055815:Young Adult
chemical_list: C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; D048493:Proto-Oncogene Proteins B-raf
keywords: BRAF-mutation; EGFR-mutation; Genetic testing; Lung cancer; Tyrosine kinase inhibitors